Application of transrectal contrast-enhanced ultrasound in the diagnosis of prostate cancer in different tPSA intervals
10.3969/j.issn.1009-8291.2023.10.007
- VernacularTitle:经直肠前列腺超声造影在不同总前列腺特异性抗原区间前列腺癌诊断中的应用
- Author:
Ming ZHANG
1
;
Qinglu GAO
1
;
Qingsong MENG
1
;
Hui TIAN
2
;
Dongbin WANG
1
;
Xin WANG
1
;
Shouquan NI
3
;
Jinchun QI
1
Author Information
1. Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
2. Department of Abdominal Ultrasound, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
3. Department of Urology, Shexian Hospital, Handan 056400, China
- Publication Type:Journal Article
- Keywords:
prostate cancer;
transrectal ultrasound;
contrast-enhanced ultrasound;
prostate specific antigen;
pathological diagnosis
- From:
Journal of Modern Urology
2023;28(10):851-855
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To investigate the clinical value of transrectal contrast-enhanced ultrasound (CEUS) in the diagnosis of prostate cancer in different total prostate specific antigen (tPSA) intervals. 【Methods】 According to serum tPSA levels, 96 patients meeting the inclusion criteria were divided into 3 groups:4-10 ng/mL, >10-20 ng/mL and >20 ng/mL groups. All patients underwent transrectal CEUS. With pathological results as reference, the diagnostic value of transrectal CEUS in different tPSA intervals was evaluated. 【Results】 Of the 96 cases, 62 were confirmed by pathology as prostate cancer and 34 as benign prostatic hyperplasia (BPH). The main perfusion characteristics of prostate cancer under CEUS were rapid enhancement (64.52%), rapid clearance (70.97%), uneven enhancement (83.87%) and high enhancement (61.29%);the main characteristics of BPH were non-rapid enhancement (70.59%), non-rapid clearance (73.53%), uniform enhancement (76.47%) and non-high enhancement (52.94%). There were significant differences in terms of enhancement speed, clearance speed and enhancement uniformity between prostate cancer and BPH (P<0.05), but no significant difference in the enhancement intensity. The sensitivity of transrectal CEUS in the diagnosis of prostate cancer in low, medium and high tPSA groups were 58.33%, 70.37% and 95.65%, the specificity were 83.33%, 76.92% and 66.67%, and the accuracy were 73.33%, 72.50% and 92.31%, respectively. Transrectal CEUS showed consistency at different serum tPSA levels for the diagnosis of prostate cancer, with statistical significance. Moreover, in the 4.0 ng/mL ≤tPSA<10.0 ng/mL group, the diagnostic specificity was the highest. 【Conclusion】 Transrectal CEUS is helpful in the differential diagnosis of benign and malignant prostatic lesions, especially for patients with different serum tPSA levels.
